Ritedose Launches New Single-Dose Syringe Product: Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL) – The Ritedose Corporation

COLUMBIA, S.C. (April 30, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the coun

Pfizer 00409488820 - McKesson Medical-Surgical

Ritedose Launches New 503B, Single-Dose Syringe Medications for

Novo Holdings buys sterile injectables maker Ritedose for

Pfizer 00409234402 - McKesson Medical-Surgical

Pfizer 00409226720 - McKesson Medical-Surgical

News – The Ritedose Corporation

Hospira 00409121501 - McKesson Medical-Surgical

Pfizer 00409233934 - McKesson Medical-Surgical

In the News – The Ritedose Corporation